与甲型流感病毒核衣壳蛋白的第 342-351 位氨基酸序列相对应。
编号：200823
CAS号：199727-68-9/2803406-00-8
单字母：H2N-RVLSFIKGTK-OH
CEF4 是一种多肽，它与甲型流感病毒核衣壳蛋白的第 342-351 位氨基酸序列相对应。
CEF4 is a peptide that corresponds to aa 342-351 of the influenza A virus nucleocapsid protein.
乙酸CEF4是与甲型流感病毒核衣壳蛋白的氨基酸序列342-351相对应的多肽。CEF肽是来自鸡胚成纤维细胞的v-Src诱导的细胞因子。
CEF4 acetate is a polypeptide that corresponds to amino acid sequence 342-351 of the influenza A virus nucleocapsid protein. CEF peptides are v-Src-induced cytokines from chicken embryo fibroblasts.
Definition
The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human Cytomegalovirus, Epstein-Barr Virus and Influenza Virus1 These peptides are used in the stimulation of IFNg release from CD8+ T cells in individuals with defined HLA types1. They are useful as positive control peptides in several cytokine assays such as Elispot.
Discovery
CEF peptides were first selected in 2002 based on their ability to recognize CD8+ T cells1.
Classification
They are derived from epitopes of viruses and hence have antigenic properties1.
Structural Characteristics
CEF peptides are 8-11 amino acids long with sequences: GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2).
Mode of action
CEF peptides are effective epitopes for CD8+ T cells2. They bind to these cells and trigger the production of IFNg.
Functions
CEF control peptides are used as positive control in Elispot assay that is used to investigate specific immune responses in various diseases including infections, cancer, allergies and autoimmune diseases2. In this case the CEF peptides ensure that the cells under study are active and viable2. Elispot is also useful in the development of vaccines especially for HIV where CEF peptides are used also as controls2.
References
1. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH (2002). A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays, J Immunol Methods, 260, 157-172.
2. Gazagne A, Claret E, Wijdenes J, Yssel H, Bousquet F, Levy E, Vielh P, Scotte F, Goupil T, Fridman WH, Tartour E (2003). A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines, J Immunol Methods, 283(1-2), 91-98.
